Avadel Pharmaceuticals PLC
AVDLDelisted Feb 12, 2026- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001012477
Avadel Pharmaceuticals PLC was delisted on Feb 12, 2026; its insiders filed their last Form 4 on Feb 18, 2026; 208 institutions reported holding it in 13F filings for Q4 2025, worth $1.60B in total; no superinvestor held it.
13F holders, Q1 2026
Institutional positions in Avadel Pharmaceuticals PLC as of Mar 31, 2026. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
AVDL is no longer listed, and 13F filings after Q4 2025 list far fewer holders. See Q4 2025
- Institutional holders
- 2
- −203 vs. Q4 2025
- Shares held
- 21
- −67.6M (−100.0%) vs. Q4 2025
- Total value
- $442
- −$1.46B (−100.0%) vs. Q4 2025
- New holders
- 0
- 0 more added
- Sold out
- 203
- 0 more reduced
3 institutions that held it in Q4 2025 haven't filed for Q1 2026 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.
Compare with Q4 2025: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting AVDL on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 1 | $16 |
| Q1 2026 | 2 | $442 |
| Q4 2025 | 208 | $1.60B |
| Q3 2025 | 188 | $1.22B |
| Q2 2025 | 174 | $721.2M |
| Q1 2025 | 177 | $613.0M |
| Q4 2024 | 160 | $837.4M |
| Q3 2024 | 176 | $979.2M |
| Q2 2024 | 156 | $1.04B |
| Q1 2024 | 126 | $1.18B |
| Q4 2023 | 113 | $795.3M |
| Q3 2023 | 99 | $559.4M |
| Q2 2023 | 101 | $856.2M |
| Q1 2023 | 93 | $443.2M |
| Q4 2022 | 83 | $239.5M |
| Q3 2022 | 76 | $157.2M |
| Q2 2022 | 82 | $82.3M |
| Q1 2022 | 81 | $244.5M |
| Q4 2021 | 85 | $287.0M |
| Q3 2021 | 82 | $314.2M |
| Q2 2021 | 80 | $219.1M |
| Q1 2021 | 77 | $294.4M |
Institutions, Q1 2026
Shares, value and share of portfolio for each institution holding Avadel Pharmaceuticals PLC; share changes are against Q4 2025.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| SBI Securities Co., Ltd. | 0 | $0 | 0.00% | −20−100.0% | Sold out |
| Essential Partners LLC | 0 | $0 | 0.00% | −11−100.0% | Sold out |
| Caitong International Asset Management Co., Ltd | 0 | $0 | 0.00% | −10−100.0% | Sold out |
| SRS Capital Advisors, Inc. | 0 | $0 | 0.00% | −8−100.0% | Sold out |
| Basecamp Wealth Advisors LLC | 0 | $0 | 0.00% | −8−100.0% | Sold out |
| Vanguard Group Inc | – | – | – | – | Not filed |
| Kotler Kevin | – | – | – | – | Not filed |
| CIBC Private Wealth Group, LLC | – | – | – | – | Not filed |